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Oligomerization of AML1-ETO contributes to leukemogenesis through obscure mechanisms. In this issue of Cancer Cell, 
Bushweller and colleagues show the crystal structure of the ETO NHR2 domain to be a tetramer. Tetramer formation is 
important for maturation arrest and self-renewal, and gene expression is altered in the absence of self-association. Loss 
of oligomer formation disrupts interactions between AML1-ETO and members of the ETO corepressor family, but not other 
corepressor molecules posited to be important for leukemogenesis. The findings clarify the role of oligomer formation in 
AML1-ETO function and suggest a possible therapeutic strategy of targeting ETO-corepressor interactions.The t(8;21) chromosomal translocation 
is a common genetic event in myeloid 
leukemias and is associated with a rela-
tively favorable prognosis. The resultant 
AML1-ETO fusion protein is thought to 
interfere with normal AML1 (RUNX1) 
function, since the AML1-ETO knockin 
mouse phenocopies AML1 knockout 
mice (reviewed in Hess and Hug, 2004). 
The mechanism of transformation has 
been studied extensively, and two key 
findings have emerged: AML1-ETO 
requires second “hits” to cause leuke-
mia, and conserved domains within ETO 
are responsible for derangement of nor-
mal AML1 transcriptional activity. These 
domains, known as Nervy homology 
regions (NHRs) based upon similarity 
with Drosophila homolog Nervy, confer 
important properties to the AML1-ETO 
fusion, including corepressor recruitment 
and self-association potential.
Self-association is crucial to the 
pathogenesis of many fusion oncopro-
teins, and may be an attractive target 
for anticancer therapy (So and Cleary, 
2004). How does oligomerization result 
in neoplasia? The mechanisms are var-
ied. The most straightforward examples 
are tyrosine kinase fusions such as the 
BCR-ABL fusion found in chronic mye-
loid leukemia: dimerization of the ABL 
kinase results in autophosphorylation, 
constitutive kinase activity, and result-
ant downstream signaling dysregulation. 
Among transcription factor oncoproteins, 
the mechanisms are less clear—but in 
general invoke altered DNA binding 
site occupancy and changes in protein 
partner affinity. For example, our group 
has reported that dimerization of MLL 
enhances DNA binding affinity and 
increases expression of target genes 
(Martin et al., 2003). However, there is 
also substantial evidence that self-asso-
ciation is insufficient for transformation: 
recent work in this journal shows that 
enforced dimerization of RARα fails to 
recapitulate the differentiation block and 
immortalization seen with PML-RARα 
expression (Licht, 2006). In many cases, 
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fusion partner are spatially inseparable 
from the dimerization domain itself: this 
overlap confounds mutation analysis of 
oncoproteins.
Oligomerization of AML1-ETO has 
been documented by several groups 
(Zhang et al., 2001, and others), and 
the activity has been mapped to NHR2. 
Self-association of AML1-ETO is not 
sufficient for the leukemic phenotype, 
since truncations retaining NHR2 do 
not exhibit full activity (Lutterbach et al., 
1998). But is oligomerization necessary? 
Although deletion of NHR2 is detrimen-
tal to AML1-ETO function, interpreta-
tion of this result is confounded by the 
multifunctional nature of the domain—it 
recruits mSin3A, for example, and 
binds histone deacetylase 2 (Amann et 
al., 2001). In this issue of Cancer Cell, 
Bushweller and colleagues use rigorous 
structural analysis to overcome this limi-
tation (Liu et al., 2006). They report that 
the NHR2 domain forms homotetram-
ers. By using crystal structure data to 
design oligomer-incompetent mutants, 
the investigators elucidate the precise 
functional contribution of AML1-ETO 
tetramer formation.
AML1-ETO is a tetramer
Bushweller and colleagues began by 
solving the crystal structure of the ETO 
NHR2 domain, which is responsible for 
self-association of AML1-ETO. Analysis 
revealed kinked α-helical monomers 
paired together in antiparallel dimers, 
each of which is in turn bundled with 
another dimer. The resultant tetramer 
forms a left-handed supercoil that bur-
ies the hydrophobic surface of each 
amphipathic monomer helix; the com-
plex is further stabilized by intermolecu-
lar salt bridges. The overall structure 
contains several familiar motifs—includ-
ing a general similarity to the super-
coiled heterotrimeric SNARE complex, 
as well as specific intermolecular con-
tacts that are seen in leucine zippers. 
However, Bushweller and colleagues 
are the first to describe an interaction nc. scheme consisting of a central tetra-
meric region of ten helical turns flanked 
by 5-turn C-terminal dimer tails at each 
end. Mass estimation by sedimentation 
velocity confirmed that, even in solu-
tion, the NHR2 domain indeed exists as 
a tetramer.
Effect of NHR2 mutation on phenotype
Solving the crystal structure of the NHR2 
domain allowed Bushweller and col-
leagues to design mutations that disrupt 
either AML1-ETO oligomerization or inter-
action with mSin3A. These precise, data-
driven substitutions represent an elegant 
improvement upon traditional slice-and-
dice modalities such as domain deletion 
and random point mutagenesis.
By comparing these mutants to wild-
type AML1-ETO and the NHR2-deleted 
fusion protein, Bushweller and colleagues 
were able to definitely attribute various 
aspects of the leukemogenic phenotype 
to tetramer formation. The investigators 
addressed the two fundamental compo-
nents of neoplastic transformation: differ-
entiation arrest and clonogenic potential. 
The NHR2 domain has previously been 
implicated in maturation arrest: whereas 
AML1-ETO expression blocks mouse 
bone marrow cell differentiation, the 
NHR2-deleted mutant impairs this capa-
bility. Bushweller and colleagues found 
that tetramer-incompetent full-length 
AML1-ETO behaved like the NHR2 dele-
tion mutant, while another tetramer-weak 
mutant showed an intermediate pheno-
type. This suggests that self-association 
contributes to the differentiation arrest that 
characterizes leukemia.
Self-renewal of AML1-ETO-express-
ing cells is also well established (Hug et 
al., 2002). Although Hug et al. (2002) have 
reported that NHR2 is dispensable for this 
function, the current work by Bushweller 
and colleagues suggests otherwise: they 
found that the NHR2 deletion as well as 
the complete and partial tetramer-incom-
petent mutants were unable to sustain clo-
nogenic activity. Interestingly, the mSin3A 
binding mutant did confer self-renewal as 
efficiently as wild-type AML1-ETO.241
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The investigators then focused on the pre-
cise functional deficiencies of tetramer-
incompetent variants. As AML1-ETO acts 
as a transcriptional activator or repressor 
in different contexts, it is not surprising that 
Bushweller and colleagues found nonuni-
form changes in gene expression when 
comparing the wild-type protein to the 
tetramer-incompetent mutant. For genes 
such as those coding for M-CSF receptor 
and neutrophil elastase, the derepres-
sion seen with the mutant correlates well 
with loss of hematopoietic differentiation 
block. Similarly, blunted activation of c-Fos 
by the mutant may contribute to its clono-
genic impotence in self-renewal assays. 
The findings suggest that oligomeriza-
tion informs transcriptional regulation by 
AML1-ETO.
Previous work has provided a long list 
of interaction partners for AML1-ETO, and 
some investigators have speculated that 
multimerization of AML1-ETO modulates 
the affinity of these factors (Zhang et al., 
2001; Hug and Lazar, 2004). By precisely 
disrupting self-association, Bushweller 
and colleagues were able to assess the 
true contribution of tetramer formation to 
partner binding. Not surprisingly, interac-
tions with wild-type ETO and ETO family 
members are lost when self-association 
of the ETO moiety of AML1-ETO is lost. 
This finding is in fact a confirmation that 
oligomer formation is impaired in the 
mutant. However, it also highlights an 
alternative interpretation of the phenotype 
experiments: perhaps loss of interaction 
between AML1-ETO and wild-type ETO 
(or another ETO family member) medi-
ates the loss of maturation arrest and/or 
self-renewal.
With the exception of ETO fam-
ily members, the tetramer-incompetent 
mutant retains affinity for all interac-
tion partners tested, including histone 
deacetylase enzymes 1–3, the core-
pressors N-CoR, SMRT, and mSin3A, 
and several other known interactors. 
In contrast, the NHR2 deletion mutant 
demonstrates impaired interaction with 
mSin3A and HDAC2—again verify-
ing the precise disruption of tetramer 
formation in the targeted mutant. The 242 retention of binding affinity for these 
cofactors by the AML1-ETO monomer 
is a surprise, as previous work suggest-
ed dependence upon the oligomerized 
state (Zhang et al., 2001) However, the 
mechanism may still be valid for other 
untested interaction partners. In addi-
tion, self-association may increase the 
local concentration of the tested factors 
by up to 4-fold—and by doing so contrib-
ute to the leukemic phenotype.
While the current study by Bushweller 
and colleagues clarifies a fundamental 
point in the AML1-ETO field, it also raises 
many interesting questions. Does heter-
otetramer formation between AML1-ETO 
and ETO family members play a role in 
pathogenesis (Figure 1)? What functional 
properties does tetramer formation pro-
vide, other than the capability of interact-
ing with other NHR2-containing proteins? 
Perhaps higher-order complex formation 
allows AML1-ETO and other transforming 
Figure 1. Functional consequences of AMl1-
ETO tetramer formation
The AMl1-ETO monomer (top) is capable of 
binding to target loci and recruiting core-
pressors and deacetylases (n-cor, msin3A, 
sMrT, HDAc1–HDAc3) but is nontransforming. 
Oligomerization of AMl1-ETO (bottom) allows 
recruitment of additional ETO family members 
and confers transforming capability. Other 
mechanisms to be defined may also contrib-
ute to the leukemogenicity of the oligomer, 
including altered DnA binding affinity, recruit-
ment of additional corepressors, or increased 
local corepressor concentration.fusion oncoproteins to function at concen-
trations far below that of their constituent 
proteins. Is DNA binding modulated by oli-
gomerization? Does tetrameric structure 
affect the ability of AML1 to heterodimer-
ize with core binding factor subunit β? 
Are other conserved domains capable of 
symmetric interaction with NHR2? With at 
least a handful of possible subunits and 
four available places in each multimer, 
the combinatorial possibilities for AML1-
ETO-containing complexes are dizzying. 
Finally, this study raises the possibility that 
disrupting oligomer formation, or more 
likely, ETO corepressor recruitment, might 
be an effective therapeutic target in this 
common form of leukemia.
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